Floatz logo

Nintedanib

Peritoneal Neoplasms

Boehringer IngelheimSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Peritoneal Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Eli Lilly and Company
Phase 3BBB
Inno-206
Eli Lilly and Company
Phase 3BBB
FLUOROURACILUM
AstraZeneca
Phase 2BB
Eloxatin
Sun Yat-sen University
Phase 2/3BB
Patupilone
Novartis Pharmaceuticals
Phase 3BB

View all 44 →

Same molecule, other indications

Nintedanib is also rated in:

idiopathic pulmonary fibrosisDormant
BBB
Indicative ·
73 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
pulmonary fibrosisDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →